Teriparatide transdermal - Zosano Pharma

Drug Profile

Teriparatide transdermal - Zosano Pharma

Alternative Names: B104; B106; Teribone™ transdermal; TH 0229; ThPTH; ThPTH (1-34); ZP-PTH

Latest Information Update: 30 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALZA Corporation
  • Developer Asahi Kasei; Zosano Pharma
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Postmenopausal osteoporosis

Highest Development Phases

  • Suspended Postmenopausal osteoporosis

Most Recent Events

  • 29 Mar 2016 Teriparatide transdermal - Zosano Pharma is available for licensing in World as of 29 Mar 2016. www.zosanopharma.com/
  • 29 Mar 2016 Suspended - Phase-I for Postmenopausal osteoporosis in Australia (Transdermal)
  • 28 Sep 2015 Eli Lilly terminates its licence for teriparatide transdermal Worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top